Inogen (NASDAQ:INGN) Earns Hold Rating from Needham & Company LLC

Needham & Company LLC reaffirmed their hold rating on shares of Inogen (NASDAQ:INGN) in a report issued on Wednesday morning,Benzinga reports.

Separately, StockNews.com upgraded shares of Inogen from a “hold” rating to a “buy” rating in a report on Monday, February 10th.

Inogen Stock Performance

Inogen stock opened at $8.11 on Wednesday. Inogen has a 52-week low of $5.82 and a 52-week high of $13.33. The firm has a 50 day moving average price of $10.20 and a two-hundred day moving average price of $10.26. The firm has a market cap of $193.16 million, a price-to-earnings ratio of -3.60 and a beta of 1.02.

Institutional Trading of Inogen

Several hedge funds have recently modified their holdings of INGN. Royce & Associates LP increased its stake in shares of Inogen by 167.4% in the 3rd quarter. Royce & Associates LP now owns 51,891 shares of the medical technology company’s stock valued at $503,000 after acquiring an additional 32,482 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Inogen by 312.5% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 174,625 shares of the medical technology company’s stock valued at $1,694,000 after acquiring an additional 132,287 shares in the last quarter. BNP Paribas Financial Markets increased its stake in shares of Inogen by 13.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 42,137 shares of the medical technology company’s stock valued at $409,000 after acquiring an additional 5,131 shares in the last quarter. Verition Fund Management LLC acquired a new stake in Inogen in the 3rd quarter valued at $106,000. Finally, Paloma Partners Management Co acquired a new stake in Inogen in the 3rd quarter valued at $126,000. Institutional investors own 89.94% of the company’s stock.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.